About Order TB-500: Independent Research Literature Digest on TB-500
What Order TB-500 Is
Order TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 (Ac-LKKTETQ) and its parent compound thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain name — Order TB-500 — is a statement about what this site does with information, not about commerce. The TB-500 research record is dense, distributed across journals in immunology, cardiac physiology, dermatology, ophthalmology, neuroscience, and sports doping science. This site puts that record into ordered, plotted, semantically classified form: findings indexed by evidence class (clinical/human, preclinical animal/in vitro, regulatory/detection), citations numbered and linked, dosage contexts labeled by species and route, and safety data separated from theoretical concerns.
The 'order' in the domain is the act of ordering information — the same act performed by a research librarian, a systematic reviewer, or a data-indexed clearing-house. It is explicitly not a commercial act. Our negative-terms list excludes order-as-purchase framing entirely.
On the 'Order' Modifier
Domain modifiers like 'order,' 'clinic,' 'doctor,' 'rx,' and 'medicine' are editorial framing devices that position the publisher's relationship to the literature — not claims about clinical services or commercial transactions.
Order TB-500 holds no commercial interest in TB-500. We do not link to vendors, do not carry affiliate relationships with suppliers, and do not include any purchase-facilitation function on this site. The editorial posture is that of an analyst's console for the TB-500 research record: a constructivist evidence index designed to make twenty-two findings, five routes of administration, and two human Phase I safety trials legible to a reader who wants to understand what the studies actually measured — not to buy anything.
If you are a researcher, clinician, or student who needs the TB-500 evidence base organized in one place, this is what we offer. If you are looking for a vendor, this is not that.
Regulatory Status of TB-500
TB-500 is not approved for human use by the FDA, EMA, or any equivalent regulatory body as of 2026. It is classified as a research compound.
Full-length thymosin beta-4 has progressed further in clinical development: Phase 2 trials in dermal wound healing (pressure ulcers, stasis ulcers, epidermolysis bullosa) demonstrated accelerated healing with good tolerability [14]. Phase 3 corneal wound healing trials have been conducted. No regulatory approval for any thymosin beta-4 indication has been granted.
Phase I human safety data for full-length IV Tβ4 exists and demonstrates acceptable profiles and dose-proportional pharmacokinetics [13][21]. No Phase I human data exists specifically for the TB-500 heptapeptide fragment.
All content on this site describes what was studied in published research protocols. No content on this site constitutes medical advice, clinical guidance, or a recommendation for human use.
TB-500 and Sports Doping Regulations
TB-500 and thymosin beta-4 are explicitly prohibited at all times by the World Anti-Doping Agency (WADA) and USADA under the S2.3 Prohibited List category: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. A Therapeutic Use Exemption (TUE) for this class of compound is not available for performance-sport competition.
Positive tests have resulted in significant athletic sanctions. The Essendon Football Club case in Australia (34 players, 2-year bans upheld) involved TB-500 administration as part of a supplements program. Individual athlete cases in other jurisdictions have also resulted in multi-year bans [2].
The LC-MS detection methodology for TB-500 in equine urine and plasma was published in 2012, establishing detection limits of 0.02 ng/mL in plasma and 0.01 ng/mL in urine — confirming that post-administration samples can be identified and quantified in doping control [2].
This site covers the regulatory status of TB-500 as a factual matter — both for the FDA approval context and the WADA prohibition, both of which are part of the evidence record.